Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE)

Eye (Lond). 2024 Dec;38(18):3610. doi: 10.1038/s41433-024-03309-5.

Naomi Wijesingha^{1

2}, Aachal Kotecha³, Philippe Margaron⁴, Sobha Sivaprasad^{5

6}

¹ UCL Institute of Ophthalmology, London, UK.
² Moorfields Eye Hospital NHS Foundation Trust, London, UK.
³ Roche Products Ltd., Welwyn Garden City, UK.
⁴ F. Hoffmann-La Roche Ltd., Basel, Switzerland.
⁵ UCL Institute of Ophthalmology, London, UK. sobha.sivaprasad@nhs.net.
⁶ Moorfields Eye Hospital NHS Foundation Trust, London, UK. sobha.sivaprasad@nhs.net.

No abstract available

Publication types